Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 7/20 | 0.45 |
| ▸ | LYN | P07948 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6527821 | 1.00 | SYK (0.45) | SYKLYNSRCBTKIRAK1 | |
| SCHEMBL6526623 | 0.88 | SYK (0.46) | SYKLYNSRCIRAK1 | |
| SCHEMBL6526576 | 0.88 | SYK (0.46) | SYKLYNSRCIRAK1 | |
| SCHEMBL12795907 | 0.87 | SYK (0.40) | SYKIRAK1CHEK1FLT3GRM2 | |
| SCHEMBL12795905 | 0.87 | SYK (0.40) | SYKIRAK1CHEK1FLT3GRM2 | |
| SCHEMBL1158851 | 0.86 | SYK (0.56) | SYKLYNSRCBTKIRAK1 | |
| SCHEMBL6524279 | 0.86 | SYK (0.56) | SYKLYNSRCBTKIRAK1 | |
| SCHEMBL6524074 | 0.86 | SYK (0.56) | SYKLYNSRCBTKIRAK1 | |
| SCHEMBL6524592 | 0.85 | SYK (0.41) | SYKLYNSRCBTKCHEK1 | |
| SCHEMBL6517948 | 0.85 | SYK (0.41) | SYKLYNSRCBTKCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | claimed |
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| WO-2011014515-A1 | 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | SYK, BTK, LYN | SYK 1/4885LYN 3/4885SRC 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.